Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

Hanmi Science plunges as Hanmi Pharmaceutical's Genentech deal spurs profit-taking

25 August 2026 · By · Wire by Fusion42

Published

25 August 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

South Korea

◆ Source

Read at biz.chosun.com →

◆ Verified

Fusion42 · 25 August 2026 · Fusion42 review

Hanmi Pharmaceutical signed a large-scale exclusive license agreement with Genentech for HM17321, a drug candidate for metabolic diseases, with upfront payment of $190 million and potential deal value up to $2.3 billion, leading to profit-taking and stock price drops for Hanmi Science and Hanmi Pharmaceutical.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Your biotech company just saw a $2.3 billion pharma deal unlock milestone payments, but rapid profit-taking means more volatile capital flows follow. You need a plan to handle share price swings when licensing big assets to global partners.

◆ Coverage

1 source · 25 Aug 2026

◆ Related on Wire

◆ Topics

Biotechlicense-agreementprofit-takingbiotechpharma-dealstock-movement